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reductions in perigonadal and perirenal fat pad weights, 
serum triglycerides and cholesterol were also observed. 
Endocrine parameters, such as glucose tolerance, serum 
insulin and leptin, were not affected. In conclusion, 
our study with perinatal exposure to PFOA in mice 
produced metabolic effects in adult offspring. This is 
most likely due to disrupted programming of metabolic 
homeostasis, but the assayed endpoints did not provide 
a mechanistic explanation. The BMDL of the program-
ming effects in our study is below the current point of 
departure used for calculation of the tolerable daily 
intake.
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Introduction
Perfluorooctanoic acid (PFOA) is a man-made compound 
that, along with other perfluorinated organic compounds, is 
able to repel both water and oils. PFOA has many applica-
tions, including coatings for fabrics and carpets, food pack-
aging paper products, fire-fighting foams, mining and oil 
well surfactants and floor polishes (Prevedouros et al. 2006). 
PFOA is resistant to degradation due to the carbon–fluorine 
bond, and this stability has led to its widespread use and 
is also responsible for its persistence in the environment. 
Although not bioaccumulative (Conder et al. 2008), PFOA 
has an estimated elimination half-life in humans of around 
4 years (Olsen et al. 2009) and has been detected globally in 
adult human serum samples at 3.6–4.3 ng/mL (Calafat et al. 
2007). Similar or lower levels were measured in serum of 
pregnant mothers at 2.6–4.0 ng/mL (Grandjean et al. 2012) 
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and in cord plasma at 0.3–2.7 ng/mL (de Cock et al. 2014). 
Dietary exposure, the main exposure route for humans, has 
been established to be below the tolerable daily intake (TDI) 
of 1.5 µg/kg bw/d (EFSA 2012). However, uncertainties 
remain about the developmental effects of PFOA (EFSA 
2008; Grandjean and Budtz-Jorgensen 2013).
Fetal and neonatal exposure occurs because PFOA can 
cross the placenta and is excreted in breast milk (Apelberg 
et al. 2007a; Henderson and Smith 2007). Animal studies 
have shown that in utero and lactational exposure to PFOA 
could lead to developmental effects such as delayed eye 
opening and a decrease in body weight (Lau et al. 2006), 
neurotoxicity (Johansson et al. 2008; Mariussen 2012) and 
mammary gland developmental abnormalities (Macon et al. 
2011; White et al. 2011b). PFOA also seems to have the 
ability to interfere with endocrine systems (Jensen and Lef-
fers 2008; White et al. 2011a). PFOA is suggested to induce 
estrogen receptor transactivity and antagonize androgen 
receptor activity in in vitro studies, although this depends 
on experimental conditions (Kjeldsen and Bonefeld-Jor-
gensen 2013). Furthermore, PFOA is particularly known to 
affect metabolism through activation of peroxisome prolif-
erator-activated receptors (PPARs; Abbott et al. 2012).
Early life exposure to endocrine disrupting compounds 
(EDCs) has been suggested to program the developing 
organism for chronic diseases later in life, such as meta-
bolic disorders (Baillie-Hamilton 2002). Epidemiological 
studies have found an association between maternal PFOA 
serum and reduced birth weight (Apelberg et al. 2007b; Fei 
et al. 2007; Maisonet et al. 2012), a known risk indicator 
for metabolic diseases later in life (Ravelli et al. 1998), but 
others found no association (Hamm et al. 2010; Washino 
et al. 2009). Moreover, a recent systematic review has con-
cluded developmental PFOA exposure results in decreased 
fetal growth in both human and non-human mammalian 
species (Lam et al. 2014). Furthermore, an epidemiological 
study shows associations of maternal PFOA concentration 
with increased BMI and waist circumference, serum insu-
lin and leptin levels, and lower adiponectin levels, particu-
larly in female offspring at the age of 20 years (Halldors-
son et al. 2012). However, a study with a wider range of 
estimated PFOA exposure early in life did not find an asso-
ciation with the risk for overweight or obesity in adulthood 
(Barry et al. 2014). In one animal study described by Hines 
et al. (2009), gestational exposure of mice to relatively low 
doses of PFOA resulted in an increase in body weight and 
insulin and leptin levels during midlife in female offspring. 
Programming by EDCs for chronic diseases later in life can 
occur through changes in the epigenome, especially the 
DNA methylation pattern (Barres and Zierath 2011; Ruchat 
et al. 2013). For example, an epidemiological study shows 
global hypomethylation in umbilical cord serum associated 
with PFOA exposure (Guerrero-Preston et al. 2010).
Given the limited and inconsistent existing data on the 
metabolic programming effects of PFOA, the goal of the 
present study was to test the hypothesis that early exposure 
to low doses of PFOA can program mice for the develop-
ment of metabolic impairment later in life. We aimed to 
model human exposure conditions closely, through use of a 
broad exposure window of both gestational and lactational 
exposure and by mimicking human dietary exposure via 
maternal feed. We applied a dose–response design, using 
a control group and a dose range of 3–3000 µg/kg body 
weight/day (µg/kg bw/d). Finally, after a latency period 
of 23–25 weeks, the adult metabolic phenotype of the off-
spring was analyzed. In the final part of the study, offspring 
were challenged with a high fat diet to test whether their 
sensitivity to energy-dense feed was affected.
Methods
Test chemical and test diets
PFOA was obtained as sodium perfluoro-n-octanoate (PFOA-
Na; CAS No. 335-95-5, purity >99 %) and kindly provided 
by Wellington Laboratories Inc., Ontario, Canada. PFOA-Na 
was dissolved in acetone and mixed with the diet (NIH-07, 
Research Diet Services, Wijk bij Duurstede, The Nether-
lands). Thereafter, acetone was allowed to evaporate, and 
this master mixture was serially diluted with a factor 3–3.3 
by adding NIH-07, and afterward, the diet was pelleted. 
In this way, seven diet groups and a control NIH-07 (blank 
acetone was added) were obtained, aiming at concentrations 
of 0, 0.017, 0.056, 0.17, 0.56, 1.7, 5.6 and 17 mg/kg PFOA 
in feed, which corresponded to 0, 3, 10, 30, 100, 300, 1000 
and 3000 µg/kg bw based on an average food consumption of 
4.5 g per mouse (average body weight of 25 g) per day. PFOA 
concentrations in test diets were confirmed by isotope dilution 
liquid chromatography mass spectrometry after extraction 
with methanol (8402, JT Baker, Deventer the Netherlands) 
and a cleanup with carbon solid phase extraction (ENVI 
Carb, 57210-U, Supelco, Zwijndrecht, the Netherlands). 
Actual PFOA concentrations in the food were 15–30 % lower 
than the nominal values. The non-purified soy-based NIH-07 
was chosen because it was originally designed to optimize 
gestation, lactation and growth of rodents, and avoiding natu-
ral phytoestrogens in the diet may have confounding effects 
(Ruhlen et al. 2008). Estrogenic and anti-estrogenic activity 
for this diet was previously analyzed to be low and absent, 
respectively (van Esterik et al. 2014).
A high fat diet (D12451, Research Diet Services, Wijk 
bij Duurstede, The Netherlands), containing 45 kcal % fat 
(lard) compared with 15 kcal % fat in the NIH-07 diet, was 
given to all F1 mice during the final weeks of the study 
(21–28 weeks of age).
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Experimental conditions
Nulliparous female C57BL/6J mice (Charles River, 
Sulzfeld, Germany) were mated with male FVB mice 
(GPL, Bilthoven, The Netherlands) to produce hybrid off-
spring, for which comprehensive background information 
of phenotype and development is available (Dollé et al. 
2011). Mice were maintained under specific pathogen-free 
conditions with a target ambient temperature of 21 °C, 
humidity of 60 % and with a 12/12 h light/dark cycle. F0 
males were single-housed in standard Macrolon type II 
cages and were fed standard laboratory chow (CRM, Tec-
nilab-BMI, Someren, The Netherlands). To avoid interfer-
ence from environmental bisphenol A (van Esterik et al. 
2014), F0 females and their pups during lactation were 
housed in polysulfone cages (Tecnilab-BMI, Someren, The 
Netherlands), and drinking water was supplied in glass bot-
tles with rubber stoppers. Cages had spruce/fir wood bed-
ding (Lignocel S 8-15; Tecnilab-BMI, Someren, The Neth-
erlands) and aspen wood shavings (Lignocel 9 S) for cage 
enrichment. Both feed and water were supplied ad libitum.
After an acclimatization period of 1 week, female F0 
mice were fed experimental diets explained above start-
ing 2 weeks before mating and continued during mating 
(1 week), gestation (3 weeks) and lactation (3 weeks). Each 
dose group had six F0 females, which were mated three by 
three with two F0 males for each dose group. We previ-
ously observed that 6–9 is a range where litter size does 
not confound postnatal growth, and therefore, two outlying 
litters of 5 and 3 pups (dose groups 3 and 3000, respec-
tively) and three litters >9 (dose groups 0, 3, 100) were 
discarded (van Esterik et al. 2014). For every dose group, 
on average 9 mice per sex (range 6–10) were included for 
follow-up through juvenile and adult stages, selecting pups 
proportionally from available litters. F1 males were sin-
gle-housed, and F1 females were housed in pairs from the 
same litter in standard Macrolon type I cages. Body weight 
was measured at postnatal day (PND) 4, 7, 14 and 21 and 
weekly from 5 weeks of age continuing until the end of the 
study. Food consumption could not be recorded reliably 
due to high spillage.
At the age of 26 weeks (males) and 28 weeks (females), 
animals were fasted for 18 h to induce a general basic met-
abolic state and glucose was measured in tail vein blood 
using the FreeStyle Lite meter and test strips (Abbott, 
Hoofddorp, The Netherlands). Subsequently, for terminal 
necropsy, mice were anesthetized by combined treatment 
with ketamine and xylazine and killed by bleeding. To max-
imize the yield, blood was extracted from the orbital vascu-
lature. Blood was then treated with Pefabloc SC (PSC) and 
PSC-Protector solution (Roche, Mannheim, Germany) to 
neutralize serine proteases. Blood was allowed to clot, cen-
trifuged, and serum samples were stored at −80 °C until 
further analysis. During necropsy, body length (nose–tail 
base) was measured and a selection of organs was weighed, 
including adrenal glands, brain, liver, femur, quadriceps 
femoris muscle, pancreas, interscapular fat, perigonadal fat 
and perirenal fat.
This study was approved by the Animal Experimenta-
tion Ethical Committee of our institute under permit num-
ber 201000078 and carried out in accordance with prevail-
ing legislation.
In vivo experiments
At 19 weeks of age, a glucose tolerance test (GTT) with 
fasting for 18 h before the start of the experiment was per-
formed in control and middle dose (300 µg/kg bw/day) 
males and females as described in van Esterik et al. (2014). 
One week later, at 20 weeks of age, an insulin tolerance test 
(ITT) was performed in the same animals as used for the 
GTT. Mice were not fasted to avoid low glucose baseline 
levels which, after an insulin injection, could lead to hypo-
glycemia. At the start of the experiment, a baseline blood 
sample was taken (0 min). Subsequently, human insu-
lin (Sigma, Zwijndrecht, The Netherlands) was injected 
intraperitoneally at a concentration of 0.6 IU/kg bw, and 
glucose was measured in tail vein blood after 15, 30, 45 
and 60 min using the FreeStyle Lite meter and test strips 
(Abbott, Hoofddorp, The Netherlands). The experiment 
was performed over two morning sessions, with 1.75 h 
between the first and last tested animal in each session, 
and animals were treated in a random order. At the age of 
22–25 weeks, control and 300 µg/kg bw/d animals were 
used for a spontaneous locomotor activity test. After an 
acclimatization period of minimal 6 h, activity of the mice 
was continuously registered on four parallel platforms for 
36 h (males) or 60 h (females), starting at the beginning of 
the dark phase (6.30 PM) of the first day. Further details are 
described in van Esterik et al. (2014).
Ex vivo experiments
For bone analysis, right tibias were cleaned from soft tis-
sue and stored in Ringer solution at −20 °C until analy-
sis. The length was measured using an electronic sliding 
caliper to the nearest 0.01 mm (IP65, Sylvac SA, Crissier, 
Switzerland). The tibias were scanned using a peripheral 
quantitative computed tomography (pQCT) system (Stratec 
XCT Research SA+) with software version 5.50 (Norland 
Stratec Medizintechnik, GmbH, Birkenfeld, Germany). The 
scans of metaphysis and diaphysis were performed at sites 
distanced 10 and 45 %, respectively, of the length from the 
growth plate. The thresholds for defining trabecular bone 
were 280 and 400 mg/cm3, while cortical bone was defined 
above a threshold of 710 mg/cm3.
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For histopathology, dissected organs were partly or 
entirely fixed in 4 % formalin for 24 h (except femur), sub-
sequently placed in 70 % alcohol and routinely embedded 
in paraffin, sectioned and stained with hematoxylin and 
eosin. Histopathological analysis of the liver comprised an 
arbitrary semiquantitative scoring of selected marks (eosin-
ophilic alteration, karyomegaly, fatty change). After routine 
histopathological reading of the sections, adipocyte size 
and proxy for adipocyte number in perirenal white adipose 
tissue (WAT) were measured as described in van Esterik 
et al. (2014). Lipid accumulation in brown adipose tissue 
(BAT) adipocytes was scored semiquantitatively in the 
interscapular fat depot. Gene expression of ucp1, a marker 
of energy expenditure through thermogenesis which con-
tributes to regulation of body weight (Kozak et al. 2010), 
was measured in BAT by qPCR for control and two dose 
groups (300 and 3000 µg/kg bw/d). Cidea is a marker of 
BAT adipocytes (Zhou et al. 2003) and was used as a nor-
malizer for the contents of BAT adipocytes in the tissue 
extracts. Relative quantification was performed by the com-
parative CT method (Schmittgen and Livak 2008). Finally, 
serum lipids and endocrine parameters were analyzed. Mil-
liplex kits (Millipore Corporation, Billerica, MA) were 
used according to the manufacturer’s protocol to measure 
serum adiponectin, ghrelin, glucagon, insulin and leptin. 
Further technical details for ucp1 expression and serum 
lipids are described in van Esterik et al. (2014).
Statistical analyses
Data were analyzed for statistically significant dose–
responses using the benchmark dose (BMD) approach 
(Slob 2002) with the PROAST software versions 38.0 and 
38.1 (www.rivm.nl/proast). In this approach, optimal mod-
els from the exponential and Hill families are fitted to data 
covering the entire study population, and a BMD with its 
5 % lower and upper bounds of the 90 % confidence inter-
val (BMDL, BMDU) is derived from the fitted models at a 
predefined benchmark response (critical effect size, CES). 
By default, the CES used in this study was 5 % for continu-
ous data, as proposed by the European Food Safety Author-
ity (EFSA 2009). The goodness of fit was determined by 
the log likelihood of each model within a family of models. 
The optimal model selected for each family was the model 
with the lowest number of parameters, which gave the 
best significant fit. By using the bootstrap method to cal-
culate the 90 % confidence interval surrounding the BMD, 
individual animals from the same litter were clustered to 
account for litter effects. In the evaluation of results, data 
which did not produce a statistically significant dose–
response with both exponential and Hill models were not 
deemed sufficiently informative for robust conclusions. 
Furthermore, data that produced dose–responses with a 
wide confidence interval (BMDU/BMDL ratio >100) were 
not considered suitable to derive a valid benchmark dose.
Growth was calculated by dividing body weight of sub-
sequent weeks by body weight at week 5, i.e., at the start 
of the F1 follow-up. Weekly maximum effect sizes of 
growth were derived from the c-parameter of growth dose–
response functions, and when no c was available, calculated 
as a difference between top dose and control (background) 
values.
Some measurements included only control and one or 
two dose groups and could therefore not be analyzed as 
dose–responses. GTT was therefore evaluated by repeated-
measures or nested (to account for litter covariance) two-
way ANOVAs (Graphpad Prism 5.0, R) to detect differ-
ences at the different time points and between the areas 
under the curve (AUC). Activity measurement, ucp1 
expression, WAT adipocyte size and the proxy for cell 
number were also tested with a nested ANOVA (R). Differ-
ences in distribution of BAT histopathology scores between 
experimental groups were tested for statistical significance 
in a two-tailed Fisher’s exact test.
Results
General toxicity and reproduction parameters
In dams, dietary exposure to 3–3000 µg/kg bw/day PFOA 
had no effect on measures of general toxicity, including 
















 E2−CED: y = a*exp(bx)
 loglik     6.14 
 var         0.0399 
 a             8.31 
 CED       445 
 b             −0.0001151 
 CES        −0.05 
 CEDL     299.1 
 CEDU    873
log10 dose PFOA (µg/kg bw)
Fig. 1  Litter size after perinatal PFOA exposure. F0 C57BL/6J mice 
were exposed via the diet 2 weeks before mating until postnatal day 
21 to PFOA doses of 0–3000 µg/kg body weight/day. Explanation of 
the dose–response graph is in Fig. 2 legend
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survival, body weight and weight gain during gestation 
(data not shown). The lack of an effect on body weight 
or body weight gain also supports that PFOA did not 
adversely affect the palatability of the feed. Average mat-
ing success rate was 73 %, yielding 32 litters with an aver-
age litter size of 7.9 (range 3–10; Fig. 1). The overall F/M 
sex ratio in the F1 generation was 0.9, and the overall sur-
vival rate was 98 %. No effects of PFOA exposure were 
found on sex ratio or survival of the F1 generation (data 
not shown). Maternal predation of pups was observed in 
three litters, however, without relation to PFOA expo-
sure, and in general, parental behavior was normal. PFOA 
appeared to have a reprotoxic effect on litter size, with 
dose groups 1000 and 3000 µg/kg bw being above the 
BMD of 445 µg/kg bw/d (Fig. 1). For this reason, analy-
ses testing only control and single dose groups were per-
formed at the non-toxic dose of 300 µg/kg bw/d (inciden-
tally also 3000 µg/kg bw/d).
Body weights
Males showed a dose-dependent decrease in body weight at 
PND4 (Fig. 2a), indicating that dosing was received prop-
erly despite the lack of measurement of internal dose. This 
effect persisted during lactation and during the post-exposure 




Fig. 2  Dose–responses of body weight at early age and in adulthood 
after perinatal PFOA exposure. C57BL/6JxFVB hybrid mice were 
perinatally exposed via maternal diet to 0–3000 µg/kg body weight/
day PFOA during gestation and lactation. Body weight at early age, 
postnatal day 4, in a males and c females. Body weight in adult-
hood, in b males (week 25) and in d females (week 27). The func-
tion of the curves is shown in the top line in the upper right corner of 
each graph, followed by parameters of significance and shape of the 
curve (loglik, var). CES, critical effect size. CED, critical effect dose; 
CEDLbt, CEDUbt, the lower and upper bound of the (two-sided) 
90 % confidence interval for the CED, calculated by the bootstrap 
method (in the text denoted as BMD, BMDL and BMDU, respec-
tively). Small symbols individuals, large symbols geometric mean 
(per dose). The analysis was done with PROAST versions 38.0-38.1
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age (Table 1). After the start of the high fat diet regime at 
week 21, this dose-dependent decrease in body weight was 
also present in weeks 22 and 23 (data not shown). Under this 
high fat diet regime (weeks 21–25), however, a PFOA dose-
dependent increase in growth occurred (Fig. 3a, b) and con-
comitantly the dose-dependent decrease in body weight was 
no longer present in the final 2 weeks of the study (Fig. 2b).  
Similar to males, female body weight was dose-depend-
ently decreased from PND4 (Fig. 2c) until adulthood (week 
21, standard diet). This effect continued under a high fat 
diet until the end of the study, week 27 (Fig. 2d), with a 
BMDL of 849 µg/kg bw/d (Table 1). Females showed a 
negative dose–response for growth that started at week 21 
under standard diet and persisted under a high fat diet dur-
ing the final weeks of the study (Fig. 3a, c).
Organ and fat pad metrics
An overview of dose–responses for organ and fat pad met-
rics is given in Table 1. In males, none of the organ and fat 
pad weights showed a dose–response, except for absolute 
and relative (to body weight) liver weights, which both 
showed a dose-dependent increase and tibia length, which 
showed a dose-dependent decrease. Female organs were not 
affected by PFOA, except for femur and tibia length, femur 
weight and weight of the quadriceps femoris muscle, which 
all showed a dose-dependent decrease (Table 1). However, 
relative to body weight, dose–responses for femur and tibia 
length and femur weight were positive, and for weight of 
the quadriceps femoris muscle, dose–responses were absent. 
Moreover, positive dose–responses of relative organ weights 
A
B C
Fig. 3  Growth throughout study and representative dose–responses 
after perinatal PFOA exposure. C57BL/6JxFVB hybrid mice were 
perinatally exposed via maternal diet to 3000 µg/kg body weight/day 
(µg/kg bw) PFOA during gestation and lactation. a Growth through-
out the study, indicated by maximum effect sizes, in males (circles) 
and in females (triangles). The line represents the change to a high fat 
diet at week 21. Representative dose–responses for growth in b males 
and c females at the end of the study. Growth is calculated by divid-
ing body weight of every week with body weight at the start of the F1 
period (week 5). For every week, a growth dose–response was pro-
duced and maximum effect size calculated. Explanation of the dose–
response graph is in Fig. 2 legend
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that did not show an effect on absolute organ weights, par-
ticularly brain and liver, were observed. Absolute and rela-
tive weights of perigonadal and perirenal fat pads showed 
negative dose–responses (Supplemental Fig. 1), with a 
BMDL of 65 µg/kg bw/d for perirenal fat pad (Table 1).
In both males and females, the observed negative 
dose–response for cortical density was weak, indicated by 
high BMDLs. In addition, in females, the negative dose–
responses for the ability to resist torsion, bending strength 
and trabecular area had BMDLs corresponding to other 
parameters (e.g., femur weight) and maximum effect sizes 
of around 10 %. However, for all three parameters, the top 
dose group showed a small variation compared with the 
seven other groups, which could be largely responsible for 
the observed dose–responses.
Histopathology
Histopathological analysis of the liver revealed foci of cel-
lular alterations, mostly of an eosinophilic appearance, 
which were nearly significantly (p = 0.07) more frequently 
observed in the PFOA-exposed males (300 and 3000 µg/kg 
combined), compared with the control males (Table 2). In 
females, controls already showed frequent occurrence of 
such foci and the distribution of grades did not statistically 
differ between control and PFOA-exposed females. A sec-
ond observation was nuclear dysmorphology, e.g., the pres-
ence of hepatocellular nuclei of varying sizes (anisokaryo-
sis) or of notably large nuclei (karyomegaly), which was 
a notable mark and nearly statistically significant (both 
sexes p = 0.06) in the PFOA-exposed males and females 
(Table 2; Fig. 4). An additional observation was PFOA 
exposure-associated fatty change of hepatocytes, mainly of 
the microvesicular type (Fig. 4), however, without statisti-
cal significant difference of distribution.
Histopathology of brown adipose tissue (interscapu-
lar fat pad) showed significant lipid accumulation in 
the PFOA-exposed males compared with control males 
(Table 3). For females, a trend for lipid depletion in PFOA-
exposed females was observed (Table 3), but the distribu-
tion between PFOA-exposed females and control females 
did not statistically differ (p = 0.097). However, in white 
adipose tissue, both adipocyte cell size (measured in peri-
renal fat pad; Fig. 5) and cell number (data not shown) 
showed no differences between PFOA-exposed males and 
control males, while for females, cell size was significantly 
decreased in PFOA-exposed animals compared with con-
trols and cell number did not differ (data not shown).
Metabolic phenotype
To explain the change in body and organ weights, other 
metabolic and energy balance-related parameters were ana-
lyzed in one (300 µg/kg) or two (300 and 3000 µg/kg) dose 
groups and control animals, including glucose homeosta-
sis [GTT, ITT, basal glucose (measured in all dose groups, 
Table 1)] and energy expenditure (physical activity, ucp1 
expression in brown adipose tissue for temperature regula-
tion). In both males and females, PFOA did not show an 
effect on any of these parameters (data not shown).
Table 2  Histopathology grades of liver
Grades were defined through a first blinded screening of sections and represent a range for focus of eosinophilic alteration (left) from no (grade 
0), moderate (grade 1), to strong (grade 3); a range of nuclear dysmorphology, e.g., anisokaryosis/karyomegaly (middle) from no (grade 0), 
moderate (grade 1), to strong (grade 2) and a range of fatty change (right) from no (grade 0), moderate (grade 2), to strong (grade 4). In this 
distribution table, numbers are counts of perinatally control and PFOA-exposed (300 and 3000 µg PFOA/kg body weight/day) individual males 
(upper) and females (bottom) with a given grade. Results for both PFOA dose groups were similar, and data have been combined for statistical 
power
a The distribution in the PFOA-exposed males versus control males is nearly statistically significant (p = 0.07) in a two-tailed Fisher’s exact test
b The distribution in the PFOA-exposed animals versus control animals in both males and females is nearly statistically significant (for both 
p = 0.06) in a two-tailed Fisher’s exact test
Eosinophilic alterationa Nuclear dysmorphologyb Fatty change
Grade 0 Grades 1, 2 Grade 0 Grades 1, 2 Grade 0 Grades 1, 2, 3, 4
Males
 Control 10 0 10 0 10 0
 PFOA 14 6 13 7 16 4
Eosinophilic alteration Nuclear dysmorphologyb Fatty change
Grades 0, 1 Grades 2, 3 Grade 0 Grades 1, 2 Grade 0 Grades 1, 2, 3
Females
 Control 7 3 9 0 10 0
 PFOA 11 8 12 7 17 2
710 Arch Toxicol (2016) 90:701–715
1 3
To further explore the metabolic phenotype, both lipid 
(cholesterol, free fatty acids, high-density lipoproteins 
and triglycerides) and endocrine parameters (leptin, ghre-
lin, adiponectin, insulin, and glucagon) were measured 
in serum. In males, none of these serum parameters were 
affected. However, in females, both cholesterol and triglyc-
erides showed a dose-dependent decrease (Supplemental 
Fig. 2) with a BMDL of 402 and 6.2 µg/kg bw/d, respec-
tively (Table 1).
Discussion
We studied whether early exposure to low doses of PFOA 
could program C57BL/6JxFVB hybrid mice for metabolic 
impairment later in life. Offspring showed a dose-depend-
ent decrease in body weight, which already existed early in 
life (PND4) and was maintained in adulthood. Furthermore, 
growth under standard diet in both sexes was not affected. 
Therefore, this can be understood as a direct developmental 
effect at the highest doses. In contrast, other developmental 
programming studies summarized in Table 4 show a body 
weight decrease in male and/or female pups, occurring 
during lactation but without follow-up or persistence into 
adulthood. Also, incidental body weight increases were 
observed in later life, although under different experimen-
tal conditions (Hines et al. 2009; Wolf et al. 2007; details 
Table 4). In our study, high fat diet countered the PFOA 
dose-related reduction in body weight in males, leading to 
a positive dose–response for growth during the high fat diet 
regime, and hence, no observed effect in body weight for 
males during the final 2 weeks of the study. The persistent 
decrease in body weight of our females until adulthood was 
worsened by a dose-dependent decreases in growth starting 
at the last week under standard diet and continuing under 
high fat diet.
The reduced femur and tibia length and weights of 
the femur and quadriceps femoris muscle in females 
also suggest that body size was affected. The ratios of 
the femur parameters to body weight showed a positive 
dose–response, however, indicating that body weight was 
more severely affected than body size. This is supported 
by a positive dose–response of relative weights of organs 
that showed no effect of absolute weights, particularly 
control  PFOA 3000
Fig. 4  Microphotographs of liver effects in males at 26 weeks after 
perinatal exposure to PFOA 3000 µg/kg body weight/day (right) as 
compared to control (left). C57BL/6JxFVB hybrid mice were perina-
tally exposed via maternal diet to 3000 µg/kg body weight/day PFOA 
during gestation and lactation. The figure illustrates lipid accumula-
tion in hepatocytes (microvesicular steatosis, showing as white vesi-
cles) and large nuclei (karyomegaly, arrows)
Table 3  Histopathology grades of brown adipose tissue
Grades were defined through a first blinded screening of sections and 
represent a range of lipid accumulation from no (grade 1), moderate 
(grade 3), to strong (grade 6) lipid accumulation. In this distribution 
table, numbers are counts of perinatally control and PFOA-exposed 
(300 and 3000 µg PFOA/kg body weight/day) individuals with a 
given grade. Results for both PFOA dose groups were similar, and 
data have been combined for statistical power
a The distribution in the PFOA-exposed males versus control males 
is statistically significant (p < 0.05) in a two-tailed Fisher’s exact test
b For females, the distribution between controls and PFOA-exposed 
females did not statistically differ but shows a trend (p = 0.097)
Malesa Femalesb
Grades 1, 2, 3 Grades 4, 5, 6 Grades 1, 2 Grade 3
Control 7 3 4 6

























Fig. 5  White adipocyte size (measured in perirenal fat pad) after 
perinatal PFOA exposure in males and females. C57BL/6JxFVB 
hybrid mice were perinatally exposed via maternal diet to PFOA dur-
ing gestation and lactation. Data reflect control animals (open bars) 
and two PFOA dose groups, 300 and 3000 µg PFOA/kg body weight/
day (striped bars), which showed similar results and were combined 
for nested ANOVA analysis. *The difference in white adipocyte size 
between PFOA-exposed females and control females is statistically 
significant (p < 0.05) in a nested ANOVA analysis
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brain and liver. In contrast, relative weights of the perigo-
nadal and perirenal fat pads maintained a negative dose–
response, as did the absolute weights. This indicates that 
relative weight decrease in these organs is stronger than 
the decrease in total body weight, and the decrease in fat 
mass may thus provide a large contribution to the decrease 
in body weight. A decrease in white fat mass was also 
observed by Hines et al. (2009) at 1-5 mg PFOA/kg bw/d. 
This decrease in fat mass could be explained by a decrease 
in white adipocyte size, not by an effect on white adipo-
cyte cell number. Decreases in the serum lipid parameters, 
cholesterol and triglycerides are in line with decreases in 
body weight and fat pad mass. In females, a hierarchy in 
sensitivity to parameters could be deduced, where serum 
triglycerides are already affected at the lowest exposure 
levels (BMDL = 6.2 µg/kg bw/d), followed by a reduction 
in fat mass (BMDL = 65 µg/kg bw/d) and finally a lower 
body weight (BMDL = 849 µg/kg bw/d for week 27). 
These changes in lipid metabolism observed in our study 
could fit with PPARα activation (Martin et al. 2007; Rosen 
et al. 2007).
Other metabolic and energy balance-related parameters 
showed no effect and thus do not contribute to the change 
in body weight. In contrast, Hines et al. (2009) found an 
increase in insulin and leptin levels (at 21–33 weeks), coin-
ciding with the increase in body weight, but similar to our 
study, no effects on glucose tolerance were observed. Dif-
ferences between our and other developmental studies, 
especially with a similar dose range (Hines et al. 2009; 
Macon et al. 2011), can be explained by differences in 
experimental conditions. For example, we applied a three 
times longer exposure than Hines et al. (2009) and Macon 
et al. (2011), potentially also leading to a different total 
dose.
We observed an increase in relative liver weights in the 
adult F1 animals, whereas other developmental studies 
reported liver effects at an early age without a follow-up 
into adulthood (Wolf et al. 2007; Yang et al. 2009), or dur-
ing adulthood, the effect did not exist anymore (Hines et al. 
2009; Macon et al. 2011; White et al. 2009). The nearly 
significant histopathological changes in PFOA-exposed 
animals (increase in eosinophilic alteration, nuclear dys-
morphology) are generally considered as age-related non-
specific alterations in the liver (Thoolen et al. 2010), sug-
gesting that PFOA affected the liver in a non-specific way.
The study design we applied mimics the continuous, die-
tary exposure of humans to PFOA (EFSA 2012). In addi-
tion, we used multiple low doses in a wide range to more 
accurately predict the shape of the dose–responses and 
calculate a BMD. We discontinued exposure after weaning 
to focus on the early life stage and explore our program-
ming hypothesis. In contrast to the elimination half-life 
of 4 years in humans (Olsen et al. 2009), the elimination 
half-life in adult mice is 17 days, ensuring that our study 
focused primarily on exposure to PFOA during the early 
sensitive period of life (2 weeks pre-mating through to 
PND21) and the long-term consequences of this exposure. 
Moreover, due to the short half-life, a steady-state level of 
PFOA in serum of mice is already reached within 1 week 
(Lau et al. 2006). Accordingly, in a developmental study 
from Wolf et al. (2007), levels in offspring lowered 40 
times within 6 weeks after maternal exposure was stopped. 
Therefore, it is unlikely that 23–25 weeks after termination 
of the actual exposure, retained PFOA is still active and the 
observed effects are a result from direct toxicity. However, 
bioaccumulation in and slow release from bones, similar 
to perfluorooctanesulfonic acid (Borg 2013), cannot be 
excluded. PFOA thus most likely exerted its effect during 
the exposure phase early in life, and the observed effects 
are a result of disrupted programming of metabolic home-
ostasis. Specifically, the latent effects on liver weight and 
fat pads and serum lipids in both sexes indicate a role for 
programming, since Xie et al. (2003) showed in adult male 
mice that decreases in body weight, white adipose mass 
and serum cholesterol return to normal levels after cessa-
tion of high PFOA exposure.
Programming could also explain differences in observed 
effects between male and female offspring. Programming 
probably comprises a complex of (epigenetic) mechanisms, 
including endocrine pathways, and sexes can respond dif-
ferently or differ in sensitivity, resulting in diverse pheno-
typic outcomes. PFOA is a suspected endocrine disruptor 
(Du et al. 2013), supported by specific effects of develop-
mental exposure to PFOA, which is known to affect female 
reproductive tissue and alter steroid hormone levels (Dixon 
et al. 2012; White et al. 2011a; Zhao et al. 2012). Such 
sexual dimorphic effects were not studied by others, since 
most developmental studies follow only female offspring 
into adulthood.
The current TDI for PFOA is established at 1.5 μg/
kg bw/d based on a BMDL10 of 300 µg/kg bw/d for liver 
effects in rodents (EFSA 2008). Most of our effects showed 
BMDLs higher than 300 µg/kg bw/d, which is in line with 
the developmental study from Lau et al. (2006). The BMDL 
for the most sensitive effect in our study, i.e., decreased 
serum triglycerides, is 6.2 µg/kg bw/d. Because this parame-
ter has borderline informative value (BMDU/BMDL = 100), 
the next lowest effect, the BMDL for perirenal fat pad weight 
in females at 65 µg/kg bw/d could be more relevant. Cor-
rection for the measured levels of PFOA in the feed, which 
were 15–30 % lower than nominal concentrations, leads to 
a BMDL of approximately 46–55 µg/kg bw/d. This develop-
mental BMDL of 46 µg/kg bw/d is more than 10 times lower 
than the most sensitive developmental BMDL of 616 µg/kg 
bw/d established by Lau et al. (2006) and 6.5 times lower 
than the BMDL10 of 300 µg/kg bw/d used for the TDI. 
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Applying our developmental BMDL of 46 µg/kg bw/d would 
lower the TDI to 230 ng/kg bw/d. However, this level is still 
a factor 15 higher than the human dietary exposure range of 
0.16–15 ng/kg bw/d in infants (EFSA 2012).
In conclusion, our study with perinatal exposure to 
PFOA in mice produced metabolic effects in offspring, 
which were more pronounced in females. This is most 
likely due to disrupted programming of metabolic homeo-
stasis, but the assayed endpoints did not provide a mech-
anistic explanation. The BMDL of effects in our study is 
below the known BMDL for developmental toxicity and 
also below the lowest BMDL used as the basis for the cur-
rent TDI established by EFSA.
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